# Apimeds (APUS) — News

APUS · AMEX · Stock

Canonical page: https://www.lighthorse.io/tickers/apus/news

## Recent headlines

- [Aequs signs long-term supply pacts with Safran](https://www.ainvest.com/news/aequs-signs-long-term-supply-pacts-safran-2610) — AInvest Wire, Oct 12, 2026
- [APIMEDS Pharmaceuticals US - Erick Frim resigns as interim chief financial officer effective immediately - SEC filing](https://www.ainvest.com/news/apimeds-pharmaceuticals-erick-frim-resigns-interim-chief-financial-officer-effective-immediately-sec-filing-2610) — AInvest Wire, Oct 1, 2026
  APIMEDS Pharmaceuticals US has announced that Erick Frim has resigned from his role as interim chief financial officer, effective immediately, according to a recent SEC filing. The resignation was submitted voluntarily and is not linked to any disagreements with the company’s operations, policies,…
- [Mindwave Innovations: Parties have not publicly disclosed aggregate dollar value of consideration under agreement.](https://www.ainvest.com/news/mindwave-innovations-parties-publicly-disclosed-aggregate-dollar-consideration-agreement-2609) — AInvest Wire, Sep 29, 2026
  Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has found itself at the center of a corporate governance dispute involving its former directors and officers, following a series of actions taken by the company’s majority stockholders. On March 20, 2026, Apimeds Korea and Inscobee Inc.,…
- [Mindwave Innovations Inc.: Mindwave Innovations expands U.S. commercial footprint with second pact to build, operate](https://www.ainvest.com/news/mindwave-innovations-mindwave-innovations-expands-commercial-footprint-pact-build-operate-2609) — AInvest Wire, Sep 29, 2026
  Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has undergone significant corporate governance changes following a stockholder action on March 20, 2026. The Majority Stockholders, representing at least 66 2/3% of the voting power, removed four directors—Elona Kogan, Jakap Koo, Carol…
- [Apimeds Pharmaceuticals US - receives 100% Korean clinic rights, 25% U.S. royalty, 25% overseas revenue participation for Apitox - SEC filing](https://www.ainvest.com/news/apimeds-pharmaceuticals-receives-100-korean-clinic-rights-25-royalty-25-overseas-revenue-participation-apitox-sec-filing-2608) — AInvest Wire, Aug 21, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).